TY - JOUR
T1 - The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females
AU - Chen, Yanxia
AU - Moutal, Aubin
AU - Navratilova, Edita
AU - Kopruszinski, Caroline
AU - Yue, Xu
AU - Ikegami, Megumi
AU - Chow, Michele
AU - Kanazawa, Iori
AU - Bellampalli, Shreya Sai
AU - Xie, Jennifer
AU - Patwardhan, Amol
AU - Rice, Kenner
AU - Fields, Howard
AU - Akopian, Armen
AU - Neugebauer, Volker
AU - Dodick, David
AU - Khanna, Rajesh
AU - Porreca, Frank
N1 - Publisher Copyright:
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
PY - 2020/2/5
Y1 - 2020/2/5
N2 - Pain is more prevalent in women for reasons that remain unclear. We have identified a mechanism of injury-free nociceptor sensitization and opioid-induced hyperalgesia (OIH) promoted by prolactin (PRL) in females. PRL signals through mutually inhibitory long (PRLR-L) and short (PRLR-S) receptor isoforms, and PRLR-S activation induces neuronal excitability. PRL and PRLR expression were higher in females. CRISPR-mediated editing of PRLR-L promoted nociceptor sensitization and allodynia in naïve, uninjured female mice that depended on circulating PRL. Opioids, but not trauma-induced nerve injury, decreased PRLR-L promoting OIH through activation of PRLR-S in female mice. Deletion of both PRLR-L and PRLR-S (total PRLR) prevented, whereas PRLR-L overexpression rescued established OIH selectively in females. Inhibition of circulating PRL with cabergoline, a dopamine D2 agonist, up-regulated PRLR-L and prevented OIH only in females. The PRLR-L isoform therefore confers protection against PRL-promoted pain in females. Limiting PRL/PRLR-S signaling pharmacologically or with gene therapies targeting the PRLR may be effective for reducing pain in a female-selective manner.
AB - Pain is more prevalent in women for reasons that remain unclear. We have identified a mechanism of injury-free nociceptor sensitization and opioid-induced hyperalgesia (OIH) promoted by prolactin (PRL) in females. PRL signals through mutually inhibitory long (PRLR-L) and short (PRLR-S) receptor isoforms, and PRLR-S activation induces neuronal excitability. PRL and PRLR expression were higher in females. CRISPR-mediated editing of PRLR-L promoted nociceptor sensitization and allodynia in naïve, uninjured female mice that depended on circulating PRL. Opioids, but not trauma-induced nerve injury, decreased PRLR-L promoting OIH through activation of PRLR-S in female mice. Deletion of both PRLR-L and PRLR-S (total PRLR) prevented, whereas PRLR-L overexpression rescued established OIH selectively in females. Inhibition of circulating PRL with cabergoline, a dopamine D2 agonist, up-regulated PRLR-L and prevented OIH only in females. The PRLR-L isoform therefore confers protection against PRL-promoted pain in females. Limiting PRL/PRLR-S signaling pharmacologically or with gene therapies targeting the PRLR may be effective for reducing pain in a female-selective manner.
UR - http://www.scopus.com/inward/record.url?scp=85079068527&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079068527&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.aay7550
DO - 10.1126/scitranslmed.aay7550
M3 - Article
C2 - 32024801
AN - SCOPUS:85079068527
SN - 1946-6234
VL - 12
JO - Science translational medicine
JF - Science translational medicine
IS - 529
M1 - eaay7550
ER -